Overview

Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of SRT2104 Administered to Normal Healthy Male Volunteers

Status:
Completed
Trial end date:
2009-05-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the pharmacokinetic profile, safety, and tolerability of SRT2104 following administration of single and multiple oral doses (once a day for seven days) at a single dose level (2.0 g/day) to healthy male volunteers in the fed state.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline